Efficacy and Safety of an Anti-nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study

Efficacy and Safety of an Anti-nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study

Background: Pain management for cats with degenerative joint disease (DJD) remains a critical unmet need. Recent work has shown promise for a feline-specific anti-nerve growth factor monoclonal antibody (frunevetmab) to deliver safe and effective pain management. Our objectives were to evaluate the...

Full description

Bibliographic Details
Main Authors: Margaret E. Gruen, Jamie A. E. Myers, B. Duncan X. Lascelles
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Veterinary Science
Subjects:
feline
osteoarthritis
DJD
monoclonal antibody
mobility
pain
Online Access:https://www.frontiersin.org/articles/10.3389/fvets.2021.610028/full

Internet

https://www.frontiersin.org/articles/10.3389/fvets.2021.610028/full

Similar Items